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Aim To test if circulating levels of markers of inflammation, 
endothelial function, and chronic infections, as well as as-
sociation between these markers and carotid intima media 
thickness (CIMT), depend on the stage of atherosclerosis 
expressed as a history of a major vascular event.
Methods The associations were analyzed separately in 75 
healthy controls, 79 patients 3-6 months after the first-ever 
non-cardioembolic ischemic stroke (IS), and 37 patients 3-6 
months after the first-ever myocardial infarction (MI). Data 
were collected prospectively in 2005. We measured high 
sensitivity C-reactive protein (hs-CRP), procalcitonin, E-se-
lectin, intercellular adhesion molecule-1 (ICAM-1), serum 
level of immune complexes (IC), and identified antibodies 
against Herpes simplex virus type 1 (HSV), Cytomegalovi-
rus, Chlamydia pneumonia, and Helicobacter pylori. Correla-
tions with CIMT were determined using Pearson R and veri-
fied after adjustment for age, sex, hypertension, diabetes, 
and statin therapy.
Results Median ICAM-1 concentration was significantly 
lower in controls than in post-IS patients (188 μg/L vs 215 
μg/L), and significantly lower in post-IS patients than in 
post-MI patients (215 μg/L vs 260 μg/L). Control patients 
also had significantly lower IC level (0.03 U/L) and HSV an-
tibody index (6.0) compared to both post-IS (0.6 U/L, 9.6) 
and post-MI (0.4 U/L, 9.2) patients. CIMT was correlated 
with age (Pearson R = 0.38, P = 0.001) in the control group, 
immune complexes (R = 0.26, P = 0.023) in the post-IS 
group, and with hs-CRP (R = 0.40, P = 0.017) in the post-MI 
group. These correlations were confirmed using multiple 
regression analysis.
Conclusions Our study supports linear correlations be-
tween CIMT and IC and hs-CRP levels. However, these asso-
ciations seem to depend on the type of vascular burden.
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Atherosclerosis is a chronic inflammatory and metabolic 
disease that may manifest as myocardial infarction (MI), 
ischemic stroke (IS) or other conditions caused by arterial 
stenosis. These acute events are usually triggered either by 
progression to a flow-limiting disease or thrombus forma-
tion on vulnerable plaque (1,2). Despite major advances in 
the prevention and treatment, stroke and coronary artery 
disease remain the leading causes of morbidity worldwide, 
accounting for approximately one third of all deaths (3).
There are currently several pathological, biochemical, and 
imaging criteria proposed to identify high risk plaques 
and high risk patients (4). Atherosclerotic plaques and ca-
rotid intima-media thickness (CIMT) are widely accepted 
as measures of the degree of atherosclerosis. Although 
highly intercorrelated, they probably reflect different bio-
logical aspects and stages of the disease (5). The presence 
of plaque indicates a higher risk of acute ischemic events 
(6,7), while CIMT without plaque is a significant marker of 
atherosclerosis and predicts plaque development (6). Both 
CIMT and the degree of stenosis may improve the predic-
tion of cerebrovascular events in patients with asymptom-
atic carotid stenosis (8). This refers especially to the sub-
populations with intermediate or high vascular risk (9).
Despite advances in visualization and grading of coro-
nary atherosclerosis, there is still a need to identify addi-
tional groups of patients who may benefit from early ini-
tiated aggressive vascular prevention (10,11). Published 
data suggests that systemic factors play an important 
role in the progression of atherosclerosis and may con-
tribute to plaque instability (2,4). However, the evidence 
supporting particular serum biomarkers is mixed and in-
conclusive, which dampened early enthusiasm (2,4). The 
usefulness of incorporating them into predictive models 
based on conventional vascular risk factors has not been 
confirmed (12).
Our aim was to investigate the relationship between CIMT 
and circulating levels of markers of inflammation, en-
dothelial function, and chronic infections in three different 
clinical stages of atherosclerosis. We chose the common 
markers that were already shown to increase in the acute 
phase of stroke or MI (12,13), but their levels in the chronic 
phase after vascular event have not been well established. 
We hypothesized that the levels of at least some of these 
biomarkers would be lower in control patients compared 
to patients after IS of non-cardioembolic etiology or after 




The study was approved by the Committee for Ethics in Hu-
man Research at the Institute of Psychiatry and Neurology 
in Warsaw, Poland and carried out in year 2005 as a part of 
larger interdisciplinary research project. Patients with a his-
tory of IS were recruited from a single stroke center, which 
provides neurological care for approximately 250 000 in-
habitants of a highly urbanized area (Warsaw). The diag-
nosis of stroke was based on clinical symptoms according 
to the WHO definition (14) and brain imaging (usually non-
contrast computed tomography). The patients were eligi-
ble for inclusion if (i) 3 to 6 months had passed after the 
first-ever ischemic stroke, (ii) they were between 55 and 85 
years old, (iii) had a negative history of atrial fibrillation or 
intracardiac thrombi, (iv) had a negative history of clinically 
manifest or silent MI, (v) had a negative history of cancer, 
and (vi) had no signs of an ongoing infection.
Patients with a history of MI were recruited from a single 
department specialized in hypertension, cardiology, and 
general medicine, which provides care for approximately 
500 000 inhabitants of a highly urbanized area (Warsaw). 
The patients were eligible for inclusion if (i) 3 to 6 months 
had passed after the first-ever MI, (ii) they were between 
55 and 85 years old, (iii) had a negative history of previous 
stroke, (iv) had none or mild symptoms of congestive heart 
failure (class I or II of the New York Heart Association Func-
tional Classification), (v) had a negative history of cancer, 
and (vi) had no signs of an ongoing infection.
The control group included other patients admitted to 
both centers and healthy volunteers recruited from staff 
and their families. The inclusion criteria were (i) age be-
tween 55 and 85 years, (ii) negative history of stroke, (iii) 
negative history of MI or coronary artery disease, (iv) nega-
tive history of connective tissue disease, (v) negative his-
tory of cancer, and (vi) no signs of an ongoing infection.
Data about vascular risk factors and concomitant medica-
tions were collected using a predefined form.
Biochemical assays
Investigated biomarkers included markers of inflamma-
tion (high-sensitivity C-reactive protein [hs-CRP], procal-
citonin, [PCT]), markers of endothelial function (inter-
cellular adhesion molecule-1 [ICAM-1], E-selectin), 
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and markers of chronic infection (immune complexes [IC]; 
the presence of antibodies to Herpes simplex virus type 1 
[HSV-1], Cytomegalovirus [CMV], Chlamydia pneumoniae 
lipopolysaccharide, and Helicobacter pylori in IC).
Fasting venous blood samples were collected from the pa-
tients who had no evidence of infection, centrifuged, and 
stored at -80°C. CRP was measured using immunoneph-
elometric method (Dade Behring N Latex High Sensitivity 
CRPTM mono assay on a Behring Nephelometer 100 ana-
lyzer, Marburg, Germany). PCT was assessed using the im-
munoluminometric assay (LUMItest PCT, BRAHMS Diag-
nostica, Berlin, Germany).
Endothelial markers were measured with ELISA using com-
mercially available kits (R&D Systems, Minneapolis, MN, 
USA for ICAM-1, and Amersham Bioscience, Amersham, 
UK for E-selectin). Absorbance at 450 nm was assessed on 
a Stat-Fax 2100 microplate reader (Awareness Technology 
Inc., Palm City, FL, USA).
The IC level was determined by selective precipitation of im-
mune complexes with polyethylene glycol (PEG) followed 
by an ELISA assay to detect the specific antigens presence 
in the precipitate, as described previously (13). Briefly, 0.3 
mL of the serum sample was added to the 6 mL of 5% PEG 
in sodium borate buffer, pH 8.4, incubated overnight at 4°C, 
and centrifuged at 2500 rpm for 20 minutes at 40°C. Pellets 
were washed twice with 3.5% PEG and dissolved with 0.3 
mL distilled water with the addition of 2.7 mL of 0.1 mol/L 
sodium hydroxide. The blind sample consisted of 0.3 mL 
distilled water and 2.7 mL of 0.1 mol/L sodium hydroxide. 
The extinction was measured on a spectrophotometer at 
280 nm. The results were expressed as OD280 and consid-
ered positive if exceeded the geometric mean of OD280 (cal-
culated from the log-transformed distribution).
The level of IgG antibodies to Helicobacter pylori, Chlamyd-
ia pneumoniae lipopolysaccharide, CMV, and HSV-1 in IC 
were measured using commercial ELISA kits, according 
to manufacturer’s protocol. Levels of IgG antibodies to H. 
pylori (Ridascreen ELISA test, R-Biopharm AG, Darmstadt, 
Germany) were expressed in units per liter (U/L). The levels 
of IgG antibodies to C. pneumoniae, CMV, and HSV-1 (VIR-
CELL, Granada, Spain) were expressed as indices relative to 
the concentrations of antibodies (antibody index = sam-
ple optical density/cut off serum mean optical density), 
as provided by the manufacturer. Serum cholesterol and 
triglyceride levels were measured using routine com-
mercial laboratory assays.
Carotid ultrasound
All examinations of CIMT and the degree of carotid steno-
sis were performed by a single experienced sonographist 
(BB-H), as described in detail elsewhere (15). Briefly, the 
participant was supine in a dark room, and the examina-
tions were done with the head held in the midline position 
or slightly tilted to either side. IMT was defined as the dis-
tance between the lumen-intima and the media-adventi-
tia of the common carotid artery (CCA) with a clearly iden-
tified double-line pattern. All measurements were done 
at the far wall on a 1-cm segment of a distal and free-of-
plaque part of CCA, using Siemens Acuson 128 XP/10 C 
scanner with 7 MHz probe (Munich, Germany) (6). Semi-
automated edge detection was used to obtain average 
CIMT across the entire distance at a resolution of 0.1 mm. 
Each measurement was repeated three times. Because 
atherosclerosis is usually not symmetrically distributed be-
tween the left and right CCA, we used the mean CIMT from 
both CCAs as a single composite measure of atherosclero-
sis. CIMT assessment was limited to CCA, as measurements 
taken in the carotid bifurcation and internal carotid artery 
are considered less reproducible and more likely to be the 
source of missing data (16).
Statistical analysis
Categorical variables are presented as the number of val-
id observations with corresponding proportions. Due to 
non-normal distribution, verified by Shapiro-Wilk test and 
visual assessment of histograms, continuous variables are 
presented as a median with the interquartile range (IQR). 
We applied Box-Cox transformation, which enabled the 
use of parametric statistics. Comparisons were made using 
χ2 test (with Yates correction if any of the expected values 
in a 2 × 2 contingency table was <5) and one-way ANO-
VA. If the overall test for significance across all three groups 
was positive (P < 0.05), post hoc pairwise comparisons were 
done using χ2 tests or t tests, as appropriate. Correlations 
between particular biomarkers and CIMT were assessed 
with Pearson rho (R) coefficient separately in each group 
of patients. They were subsequently verified in multiple 
regression models adjusted for age, sex, hypertension, 
diabetes, and the use of statins. Data collection was not 
preceded by power calculation but to improve the exter-
nal validity of obtained results, we additionally calculated 
power according to rho for the lowest number of observa-
tions in each study group (Figure 1). STATISTICA software 
package ver. 10.0 (Stat Soft Inc., Tulsa, OK, USA) was used 
and a P value of <0.05 was considered significant.




Among 194 participants there were 76 (39.2%) controls 
without any past ischemic event, 80 (41.2%) post-IS pa-
tients, and 38 (19.6%) post-MI patients. All groups were 
balanced in terms of age, sex, and smoking status (Table 
1). Compared to the control group, patients from both 
post-IS and post-MI group were significantly more often 
hypertensive and diabetic; more often used antiplatelets, 
antihypertensives, and statins; and had higher mean CIMT 
(Table 1). The proportion of patients with >60% internal 
carotid stenosis was highest in the post-IS group (Table 
1). The post-MI group showed the highest prevalence of 
congestive heart failure and atrial fibrillation, the highest 
use of antihypertensives and statins, as well as the lowest 
level of total cholesterol and the lowest alcohol consump-
tion (Table 1).
Median concentration of ICAM-1 was lowest in controls 
(188 μg/L), significantly higher in post-IS group (215 μg/L), 
and then significantly higher in post-MI group (260 μg/L). 
Compared to controls, both post-IS and post-MI groups 
showed significantly higher levels of IC and HSV-1 anti-
bodies. Levels of other biomarkers were similar across all 
groups. There was a tendency toward higher levels of E-
selectin in the post-IS group and particularly in post-MI 
group but it did not reach significance (Table 2).
Correlations between CIMt and other factors
In the control group, CIMT moderately correlated with age 
(Pearson R 0.38, P = 0.001), which was confirmed in the 
multivariate model adjusted for age, sex, hypertension, di-
abetes, and the use of statins, as well as in the sensitivity 
analysis (Table 3).
In the post-IS group, CIMT modestly correlated with IC lev-
el (Pearson R 0.26, P = 0.023), which was confirmed after ad-
justment for age, sex, arterial hypertension, diabetes and 
use of statins. However, this association lost significance in 
the sensitivity analysis (Table 3).
In the post-MI group, CIMT moderately correlated with hs-
CRP (Pearson R 0.40, P = 0.017) and triglycerides (Pearson R 
0.38, P = 0.046). The correlation with hs-CRP was confirmed 
both in the multivariate model and sensitivity analysis. 
However, the correlation with triglycerides became non-
significant after adjustment for confounding variables (Ta-
ble 3). No other associations between CIMT and investigat-
ed biomarkers were detected (Table 3).
DISCuSSIon
We found that CIMT was correlated with the level of 
immune complexes in chronic post-IS patients and 
FIGure 1. relation of power to Pearson rho in three groups of 
participants.
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with hs-CRP in post-MI patients, while no significant cor-
relations were found in the control group. Thus, our study 
adds to the existing pool of data about usefulness of sev-
eral biomarkers of inflammation, chronic infection, and 
endothelial function in different groups of patients for ap-
proximating the degree of atherosclerosis. Their relevance 
appears to depend on the type of vascular burden.
Intima media is composed of smooth muscle cells (media 
layer, 80%) and endothelium (intima, 20%), which cannot 
be distinguished by ultrasound imaging (5). There are still 
no accepted standards on how to use of IMT in various re-
search areas (15). However, it is generally agreed that early 
diffused IMT reflects not only atherosclerosis but also com-
pensatory remodeling caused by hypertensive hypertro-







n value n value n value overall P differences*
Carotid intima media thickness (mm), median (IQr) 76 0.80 (0.70; 1.00) 80 1.00 (0.90; 1.10) 38 0.90 (0.80; 1.20) <0.001 cs, cm
Basic characteristics
age, median (IQR) 76 62.5 (58; 72) 80 66 (60; 72.5) 38 67.5 (62; 73) 0.141
women, No. (%) 76 43 (56.6) 80 33 (41.3) 38 21 (55.3) 0.123
arterial hypertension, No. (%) 76 36 (47.4) 80 57 (71.3) 38 28 (73.7) 0.002 cs, cm
congestive heart failure, No. (%) 76 3 (4.0) 80 2 (2.5) 38 11 (29.0) <0.001 cm, sm
atrial fibrillation, No. (%) 76 1 (1.3) 80 0 (0.0) 38 4 (10.5) 0.002 cm, sm
coronary artery disease, No. (%) 76 0 (0.0) 80 18 (22.5) 38 38 (100.0) <0.001 cs, cm, sm
internal carotid artery stenosis >60%, No. (%) 76 2 (2.6) 80 16 (20.0) 38 2 (5.3) 0.001 cs, sm
diabetes, No. (%) 76 10 (13.2) 80 21 (26.3) 38 13 (34.2) 0.025 cs, cm
current smoking, No. (%) 73 28 (38.4) 77 34 (44.2) 38 13 (34.2) 0.558
alcohol consumption, No. (%) 67 27 (40.3) 71 38 (53.5) 36 5 (13.9) <0.001 cm, sm
total cholesterol (mmol/L), median (IQR) 71 5.6 (4.9; 6.6) 76 5.3 (4.6; 6.3) 32 4.9 (4.0; 5.6) 0.002 cm, sm
triglycerides (mmol/L), median (IQR) 61 1.3 (0.9; 1.7) 67 1.2 (0.9; 1.7) 28 1.5 (1.0; 1.8) 0.361
Medications
antiplatelets, No. (%) 76 15 (19.7) 80 62 (77.5) 38 35 (92.1) <0.001 cs, cm
antihypertensives, No. (%) 76 32 (42.1) 80 47 (58.8) 38 34 (89.5) <0.001 cs, cm, sm
statins, No. (%) 76 6 (7.9) 80 40 (50.0) 38 35 (92.1) <0.001 cs, cm, sm
oral anticoagulants, No. (%) 76 1 (1.3) 80 4 (5.0) 38 4 (10.5) 0.086
*cs – significant difference between control group and post-ischemic stroke group; cm – significant difference between control group and post-
myocardial infarction group; sm – significant difference between post- ischemic stroke and post-myocardial infarction group; IQr – interquartile 
range.






infarction group Pairwise 
n median (IQr) n median (IQr) n median (IQr) overall P differences*
High sensitivity C-reactive protein (mg/L) 75 2.1 (1.3; 3.5) 79 2.6 (1.5; 5.5) 35 2.8 (1.5; 6.8) 0.156
Procalcitonin (μg/L) 74 0.00 (0.00; 0.11) 78 0.00 (0.00; 0.10) 37 0.00 (0.00; 0.10) 0.660
Intercellular adhesion molecule-1 (μg/L) 70 188 (136; 250) 79 215 (160; 295) 35 260 (218; 350) <0.001 cs, cm, sm
E-selectin (μg/L) 70 8.2 (4.0; 13.0) 79 10.5 (4.5; 20.0) 35 14.5 (6.0; 21.5) 0.131
Immune complexes (U/L) 75 0.03 (0.02; 0.03) 79 0.06 (0.03; 0.11) 37 0.04 (0.03; 0.09) <0.001 cs, cm
Helicobacter antibodies (U/L) 75 1.0 (0.6; 3.5) 79 2.0 (0.9; 5.3) 35 2.3 (0.6; 5.0) 0.101
Herpes simplex virus type 1 (antibody index)75 6.0 (4.8; 9.1) 78 9.6 (7.5; 12.1) 37 9.2 (6.5; 10.8) <0.001 cs, cm
Cytomegalovirus (antibody index) 73 7.1 (3.4; 12.6) 79 7.1 (3.9; 12.9) 35 8.4 (5.0; 12.5) 0.769
Chlamydia (antibody index) 72 6.4 (4.3; 11.3) 79 7.6 (3.3; 12.7) 35 8.6 (4.5; 13.4) 0.394
*cs – significant difference between control group and post-ischemic stroke group; cm – significant difference between control group and post-
myocardial infarction group; sm – significant difference between post- ischemic stroke and post-myocardial infarction group; IQr – interquartile 
range.
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phic response of the muscle cells to changes in local shear 
and tensile stress (5,6). On the other hand, plaque is a local-
ized manifestation of atherosclerosis, which is more likely 
related to inflammation, oxidation, endothelial dysfunc-
tion, and⁄or smooth muscle cell proliferation (5).
Carotid and coronary atherosclerosis have common risk 
factors, including hypertension, smoking, diabetes, older 
age, and dyslipidemia (17,18). In our study, age was asso-
ciated with CIMT only in controls. This may be explained 
by the fact that only individuals with advanced stage of 
atherosclerosis may experience a non-cardioembolic IS 
or MI. There was also an unadjusted correlation between 
CIMT and triglyceride concentration in post-MI patients, 
whereas the correlation with cholesterol was found in 
none of the investigated groups. One may speculate that 
intensive statin therapy initiated in almost every case af-
ter MI significantly reduces LDL cholesterol levels. There-
fore, high triglycerides may also partly reflect the extent of 
dyslipidemia that preceded the acute vascular event. On 
the other hand, the relationship between dyslipidemia and 
stroke is not clearly established and the preventive role of 
statins can most likely be attributed to the modulation of 
endothelial function and inflammatory processes (18-20). 
It should also be noted that the pleiotropic effect of statin 
therapy may involve biomarkers and result in CIMT regres-
sion (18,20). However, the time from the ischemic event to 
enrollment was probably too short to allow for significant 
changes in CIMT.
The histopathology of carotid atherosclerotic is similar to 
that of coronary atherosclerosis. However, IS results main-
ly from plaque rupture or embolization from ulcerated 
plaques, whereas MI more likely results from erosion and 
static thrombotic occlusion (21). Therefore, the usefulness 
of particular biomarkers for predicting plaque instability in 
those two vascular beds may be different (10). In our study 
there was no significant difference between CIMT in post-
IS and post-MI group. These results are in line with data 
from a large European cohort (22).
Markers of inflammation
Low-level artery wall inflammation is involved in all stages 
of atherogenesis. However, despite extensive studies, it has 
not been fully established whether serum hs-CRP plays an 
active role or whether it simply reflects other pathologi-
cal processes (23,24). We found a moderate positive cor-
relation between CIMT and hs-CRP in patients with a his-
tory of MI. This correlation was independent of age, sex, 
hypertension, diabetes, and statin therapy. However, it was 
not found in the post-IS group and control group. Previous 
studies showed that higher hs-CRP levels were associated 
with higher coronary risk but were less likely to indicate 
high-risk carotid atherosclerosis (23,25-28). Therefore, our 
results add to the pool of evidence supporting the poten-
tial usefulness of CRP for the detection of vulnerable car-
diac patients. It should also be noted that the addition of 
hs-CRP to the predictive model including conventional risk 







unadjusted multivariable* unadjusted multivariable* unadjusted multivariable*
Pearson rho Beta P Pearson rho Beta P Pearson rho Beta P
Basic factors
age (years) 0.38 (P = 0.001) 0.36 0.003 0.09 0.19 0.098 -0.05 -0.19 0.237
cholesterol (mmol/L) 0.07 0.11 0.372 0.03 -0.01 0.922 -0.04 0.01 0.943
triglycerides (mmol/L) 0.15 0.18 0.166 0.11 0.02 0.886 0.38 (P = 0.046) 0.33 0.071
Biomarkers
high sensitivity C-reactive protein (mg/L) 0.07 0.01 0.936 0.04 -0.04 0.725 0.40 (P = 0.017) 0.38 0.017
procalcitonin (μg/L) 0.08 0.04 0.721 -0.05 -0.05 0.626 0.00 -0.07 0.706
intercellular adhesion molecule-1 (μg/L) 0.09 0.09 0.439 -0.06 -0.08 0.464 0.02 0.23 0.210
E-selectin (μg/L) 0.02 -0.01 0.946 0.09 0.11 0.362 0.00 -0.05 0.732
immune complexes (U/L) 0.10 0.06 0.576 0.26 (P = 0.023) 0.23 0.042 -0.06 0.04 0.815
Helicobacter antibodies (U/L) 0.03 -0.03 0.820 -0.05 -0.06 0.571 -0.08 0.00 0.983
Herpes simplex virus type 1(antibody index) 0.09 0.02 0.864 -0.07 -0.03 0.770 -0.11 -0.04 0.782
Cytomegalovirus (antibody index) 0.16 0.05 0.662 -0.05 0.01 0.959 -0.06 -0.05 0.789
Chlamydia (antibody index) 0.13 -0.03 0.793 -0.02 -0.06 0.585 0.06 0.05 0.753
*Multiple regression models include age, sex, arterial hypertension, diabetes, and use of statins. Significant values are marked in gray.
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factors from the Framingham score only mildly improved 
risk discrimination (24).
We did not observe a correlation between CIMT and PCT, 
a marker of systemic response to bacterial infection. Previ-
ous studies showed that PCT may predict long term car-
diovascular mortality (29,30). However, PCT was associated 
with established vascular risk factors and was not superior 
to hs-CRP (29,30). It also failed to identify patients with un-
stable carotid stenosis (31).
Markers of chronic infection
Previous studies suggest that chronic infections may be 
involved in atherogenesis (32,33). Several bacterial and vi-
ral pathogens have been detected in human plaques or 
in normal vessel wall. However, the exact mechanisms of 
action and potential causality are still far from being ful-
ly understood (32,33). Our findings support the hypoth-
esis that the chronic inflammatory processes provoked or 
exaggerated by immune complexes and their accumula-
tion in vessel wall may contribute to the development of 
atherosclerosis, resulting in an ischemic event, particularly 
stroke. Although HSV antibody index was higher in both 
vascular groups compared to controls, none of the evalu-
ated pathogens showed clear relationship with CIMT. We 
are not able to determine which antigens were responsi-
ble for the increased IC level. Nonetheless, our study adds 
negative data to the pool of mixed-positive evidence for 
C. pneumoniae and mixed evidence for H. pylori, CMV, or 
HSV (31-33). Of course, our results do not exclude the po-
tential role of these biomarkers in the acute phase of IS 
or MI (13).
Markers of endothelial function
Another factor probably involved in the promotion or exac-
erbation of atherosclerosis is endothelial dysfunction (34-
36). However, despite extensive studies this is not support-
ed by strong evidence (34-36). In our study, ICAM-1 levels 
were lowest in the control group, moderately elevated in 
post-IS group, and highest in post-MI group. However, we 
did not find any correlation between ICAM-1 and CIMT in 
any of the evaluated groups. As for E-selectin, there were 
neither intergroup differences nor correlations with CIMT. 
However, previous studies suggest that sICAM-1 may be 
an early biomarker indicating disturbance of the endothe-
lium and the presence of advanced plaque in the coro-
nary and carotid arteries (37,38). Some studies also re-
port that its concentration increases especially after 
or in the course of ischemic episode, which may imply its 
involvement in carotid plaque destabilization (37). ICAM-1 
and E-selectin (but not vascular cell adhesion molecule 1) 
have also been shown to predict carotid artery atheroscle-
rosis and development of coronary heart disease (39). This 
effect can be partly attenuated by the use of statins, which 
in turn increases nitric oxide generation and reduces cir-
culating levels of ICAM-1 and P-selectin in hypercholester-
olemic patients (40).
Strengths and limitations
A restricted number of individuals is a common limitation 
in studies investigating multiple biomarkers of one patho-
logical condition but it needs to be noted, especially in the 
post-MI group. The sample size in our study is similar to 
what has been reported in other biomarker studies (11,31). 
It was not based on power calculations because the aim of 
the study was to address several biomarkers without priori-
tizing any of them. This should be taken into account while 
interpreting the results, especially in the post-myocardial 
infarction group. We may not exclude that larger sample 
size would yield significant correlations between CIMT and 
other biomarkers. However, to make the analysis more ro-
bust we applied Box-Cox transformation, which enabled 
the use of parametric statistics. Our intention was to car-
ry out an exploratory analysis that would identify associ-
ations of potential clinical importance. Judging from the 
point estimates, even if the association was proven signifi-
cant after doubling or tripling the number of participants, 
its strength would be low and without any clinical implica-
tions. It needs to be noted that the control group consisted 
of both healthy volunteers and non-stroke or non-coronary 
artery disease patients, which was intended to better re-
flect general population but may have also been a source 
of bias, since it does not ensure full representativeness of 
the control group for the general non-stroke and non-MI 
population. Blood samples were taken only once, which 
may have introduced bias caused by intraindividual varia-
tion. Detailed lipid profile was not assessed in all patients 
and therefore the levels of LDL and HDL cholesterol were 
not reported. All patients had already entered the chron-
ic stage of disease, meaning that many of them were us-
ing statins at least for several months, which may have af-
fected the levels of inflammatory biomarkers. However, the 
levels measured early after IS and MI do not reflect their ev-
eryday levels and clearly decrease over time, which makes 
them less reliable for long-term risk stratification (13,41). All 
patients were Caucasians recruited from one geographi-
cally homogenous area, which excludes potential ethnical 
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bias (42). They were also subjected to identical diagnostic 
procedures carried out by the same group of investigators, 
which made direct comparisons fully justified.
Conclusions
Considering differences between pathologies leading to 
symptomatic coronary or carotid ischemic events, it may 
be difficult to identify a single universal blood marker of 
atherosclerosis that would significantly improve present 
clinical predictive models. Nonetheless, there is still need 
for further well designed and large scale studies of novel 
biomarkers.
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